Lexeo Therapeutics, Inc. Common Stock (LXEO) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -21.14M | -20.08M | -29.55M | -27.22M | -21.72M | -28.33M | -17.81M | -20.15M | -14.87M | -13.98M | -13.95M | -13.19M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 2.63% | 29.11% | -65.94% | -35.07% | -46.07% | -102.6% | -27.65% | -52.77% | 19.09% | 15.91% | - | - |
| Net Income | -20.2M | -20.92M | -20.28M | -26.1M | -32.66M | -25.92M | -29.49M | -21.24M | -21.68M | -14.19M | -20.11M | -13.44M |
| Depreciation & Amortization | 31K | 921K | 530K | 510K | 501K | 521K | 509K | 496K | 476K | 490K | 460K | 446.06K |
| Stock-Based Compensation | 2.75M | 2.71M | 2.65M | 3.07M | 3.7M | 3.51M | 3.79M | 2.85M | 2.33M | 0 | 873K | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 473K | -395K | 60K | -3.36M | 12K | -23K | 0 | 0 | 0 | 1.06M | 272K | 968.23K |
| Working Capital Changes | -4.21M | -2.4M | -12.51M | -1.34M | 6.73M | -6.41M | 7.38M | -2.26M | 4.01M | -1.35M | 4.55M | -1.16M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.6M | 200K | -15.27M | 8.36M | 5.14M | -2.04M | 2.72M | 1.06M | 639K | 394K | 290K | -1.91M |
| Cash from Investing | 27.46M | -101.69M | 35.01M | -39.17M | 15.6M | -93.58M | -83K | -218K | -193K | -73K | -53K | -39K |
| Capital Expenditures | -35K | 0 | -289K | -108K | 0 | 13K | -83K | -213K | -185K | -73K | -53K | -39K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 17K | 0 | 0 | 0 | 0 | 0 | -5K | -8K | 0 | 0 | 0 |
| Cash from Financing | 2.45M | 143.77M | 52K | 72.96M | 11K | -97K | -72K | 291K | 88.65M | 100.07M | 3.91M | -94.56K |
| Debt Issued (Net) | -121K | -169K | -83K | -122K | -159K | -116K | -111K | -74K | -109K | -191K | 3.89M | -103.42K |
| Equity Issued (Net) | 2.57M | 143.94M | 101K | 80M | 170K | 19K | -6.29M | -54K | 88.75M | 100.25M | 30K | 8.86K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -4K | 0 | -13K | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 34K | -6.92M | 0 | 0 | 6.33M | 419K | 10K | 11K | -11K | 0 |
| Net Change in Cash | 8.77M | 22M | 5.52M | 6.57M | -6.11M | -122.01M | -17.96M | -20.08M | 73.59M | 86.02M | -10.09M | -13.31M |
| Free Cash Flow | -21.18M | -20.08M | -29.84M | -27.33M | -21.72M | -28.31M | -17.89M | -20.37M | -15.06M | -14.05M | -14M | -13.23M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 2.47% | 29.08% | -66.78% | -34.15% | -44.2% | -101.46% | -27.76% | -53.97% | 18.04% | 16.01% | - | - |
| FCF per Share | -0.26 | -0.26 | -0.49 | -0.63 | -0.66 | -0.86 | -0.54 | -0.62 | -0.54 | -0.51 | -0.56 | -0.53 |
| FCF Conversion (FCF/Net Income) | 1.05x | 0.96x | 1.46x | 1.04x | 0.66x | 1.09x | 0.60x | 0.95x | 0.69x | 0.99x | 0.69x | 0.98x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |